These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 15550578

  • 41. A decade of letrozole: FACE.
    O'Shaughnessy J.
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):67-74. PubMed ID: 17912637
    [Abstract] [Full Text] [Related]

  • 42. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group.
    Cancer; 2003 Nov 01; 98(9):1802-10. PubMed ID: 14584060
    [Abstract] [Full Text] [Related]

  • 43. Obesity and endocrine therapy: host factors and breast cancer outcome.
    Goodwin PJ.
    Breast; 2013 Aug 01; 22 Suppl 2():S44-7. PubMed ID: 24074791
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J.
    Clin Ther; 2005 Nov 01; 27(11):1671-84. PubMed ID: 16368441
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Evolving uses of hormonal agents for breast cancer therapy.
    Cummings FJ.
    Clin Ther; 2002 Nov 01; 24 Suppl C():C3-25. PubMed ID: 12117074
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. A roundtable discussion of aromatase inhibitors as therapy for breast cancer.
    Allred DC, Baum M, Buzdar AU, Carlson RW, Dowsett M, Elledge RM, Gradishar WJ, Grana G, Howell A, Mamounas EP.
    Breast J; 2003 Nov 01; 9(3):213-22. PubMed ID: 12752630
    [Abstract] [Full Text] [Related]

  • 51. Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
    Michaud LB.
    Am J Health Syst Pharm; 2005 Feb 01; 62(3):266-73. PubMed ID: 15719584
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. The role of aromatase inhibitors in the treatment of metastatic breast cancer.
    Mouridsen H, Gershanovich M.
    Semin Oncol; 2003 Aug 01; 30(4 Suppl 14):33-45. PubMed ID: 14513435
    [Abstract] [Full Text] [Related]

  • 54. Should aromatase inhibitors replace tamoxifen?
    Drug Ther Bull; 2003 Aug 01; 41(8):57-9. PubMed ID: 12966738
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
    Sainsbury R.
    Br J Cancer; 2004 May 04; 90(9):1733-9. PubMed ID: 15150604
    [Abstract] [Full Text] [Related]

  • 58. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
    Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P.
    Curr Med Res Opin; 2006 Aug 04; 22(8):1575-85. PubMed ID: 16870082
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
    Ingle JN.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 2):1031s-1036s. PubMed ID: 16467121
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.